- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00322738
Time to Infection With Malaria Parasites
January 30, 2019 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
Time to Infection With Malaria Parasites in Adults
This study will attempt to find out what effect mosquito insecticides have on the transmission of malaria in The Gambia.
Eight hundred healthy men and women, aged 18 to 40 years, living in selected villages east of Farafenni town in The Gambia, West Africa will be screened for parasites.
About 552 of these people are expected to be free of malaria and will form the study group.
These people will participate in the study for 7 months and will be checked for the malaria-causing parasite every two weeks by finger prick blood sample.
Study Overview
Status
Completed
Conditions
Detailed Description
Malaria remains one of the world's greatest childhood killers and is a substantial obstacle to social and economic development in the tropics.
The overwhelming bulk of the world's malaria burden rests upon the population of sub-Saharan Africa because of the unique coincidence of expanding human populations, weak health systems, the world's most effective vector mosquito species and environmental conditions ideal for transmission.
At the start of the new millennium malaria is still deeply entrenched in Africa and effective malaria control is under threat from the inexorable spread of parasite strains resistant to antimalarial drugs and the emergence of mosquitoes resistant to the pyrethroid insecticides used to impregnate bednets.
Larval control may offer a new alternative for effective control.
Mosquito larval control strategies (environmental management and larviciding) have historically been shown to be successful in reducing the abundance of mosquitoes.
This study plans to apply a larvicide in an effort to control malaria and reduce the burden of malaria.
While it is abundantly clear that this product will kill mosquito larvae in the laboratory and in the field, it is not certain that doing so will reduce the burden of malaria for the human population.
Briefly, the steps involved include survival and development of immature mosquito stages, emergence of adult mosquitoes, blood feeding by those mosquitoes, acquisition and development of malaria parasites by adult mosquitoes and transmission of parasites to susceptible humans.
The objective of this pilot study is to evaluate the use of the time-to-infection end point as a measure of malaria transmission in The Gambia, while mosquito larvicides are used to control malaria vectors.
The main outcomes of this study are (1) the proportion of adults with detectable parasitemia (Plasmodium falciparum) that is a binary variable and (2) time-to-infection with malaria parasites that will be treated as a continuous variable.
This experimental design takes place over 7 months.
The target sample size is 800 adults (aged 18-40 years, approximately half will be women and half men) living in 50 villages east of Farafenni town in The Gambia, West Africa.
It is estimated that 552 of the adults will have no detectable parasites in their blood at the beginning of the transmission season (June).
These parasite negative individuals will be followed either for the duration of the transmission season (June through November) or until they become positive for parasites.
Study Type
Observational
Enrollment
2558
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fajara, Gambia
- Medical Research Council's Laboratories
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adults living in the selected villages who consent to join the study,
- between the ages of 18 to 40 years old, and
- free of clinical signs or symptoms of illness at recruitment.
Exclusion Criteria:
- Adults who do not consent to join the study,
- sick men and women (i.e., have clinical signs or symptoms of illness),
- men and women 41 years or older, or
- children.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 7, 2006
Primary Completion (Actual)
March 31, 2008
Study Completion (Actual)
March 31, 2009
Study Registration Dates
First Submitted
May 4, 2006
First Submitted That Met QC Criteria
May 4, 2006
First Posted (Estimate)
May 8, 2006
Study Record Updates
Last Update Posted (Actual)
February 1, 2019
Last Update Submitted That Met QC Criteria
January 30, 2019
Last Verified
November 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-0067
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasmodium Falciparum Malaria
-
SanofiMedicines for Malaria VentureCompletedPlasmodium Falciparum InfectionBenin, Burkina Faso, Gabon, Kenya, Uganda
-
SanofiMedicines for Malaria VentureTerminatedPlasmodium Falciparum InfectionBenin, Burkina Faso, Gabon, Kenya, Mozambique, Uganda, Vietnam
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesCompletedUncomplicated Plasmodium Falciparum MalariaTanzania
-
David SaundersNational Centre for Parasitology, Entomology and Malaria Control, Cambodia; Royal Cambodian Armed Forces and other collaboratorsSuspendedUncomplicated Plasmodium Falciparum MalariaCambodia
-
University of OxfordEuropean CommissionCompletedMalaria | Plasmodium FalciparumUnited Kingdom
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompletedAcute Uncomplicated Plasmodium Falciparum MalariaThailand, Gabon, Mali, Uganda, Burkina Faso, India, Kenya, Mozambique, Vietnam
-
Syamsudin Abdillah,Ph.D, Pharm DApt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati...CompletedUncomplicated Plasmodium FalciparumIndonesia
-
PfizerCompletedPLASMODIUM FALCIPARUM MALARIAIndia
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical...CompletedMalaria, Plasmodium FalciparumThe Gambia